ICICI Securities: GSK Pharma Sees Sequential Growth As Business Recovers From Covid-19 Impact
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
GlaxoSmithKline Pharmaceuticals Ltd.’s Q2 FY21 results were better than our estimates.
Revenue remained flat YoY at Rs 8.8 billion (our estimate Rs 8.2 billion), Ebitda margin improved 130 basis points YoY (up 570 basis points QoQ) to 23.3% (our estimate 22.9%) while adjusted profit after tax declined 27.8% YoY to Rs 1.2 billion (our estimate Rs 1.3 billion).
Better than expected performance was driven by steady recovery in top brands with easing of lockdown.
We expect this trend in recovery in the acute therapies to continue in the coming quarters.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.